Employee Experience Specialist

Model N acquires Kalderos to expand its 340B capabilities and gross-to-net revenue management. June 17, 2026 Deal adds claims-level visibility to help manufacturers identify duplicate discounts earlier and reduce revenue leakage REDWOOD CITY, Calif., June 17, 2026 - Model N, a leading end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies, announced it has acquired Kalderos, a technology company that provides a gross-to-net (GTN) intelligence platform with rich capabilities for driving visibility into 340B drug discount programs. The acquisition will expand Model N's capabilities as a leading revenue management platform for life sciences manufacturers and extend its 340B offerings to better serve customers. 340B, a federal program that requires drug manufacturers to sell outpatient drugs at discounted prices to eligible safety-net hospitals and clinics, is a core and growing component of the overall GTN value chain. Manufacturers are managing 340B amid Medicare drug price negotiations, potential future pricing models such as most-favored-nation (MFN), and growing scrutiny of 340B claims-level data requirements. These pressures are increasing the need to identify discount discrepancies and optimize revenue. Model N's 2026 State of Revenue Report found that only 1% of life sciences revenue leaders have real-time visibility into 340B discounts, Medicaid and Medicare rebates, and utilization rebates. Kalderos' Truzo solution directly addresses these challenges through an end-to-end drug discount management platform that provides real-time data visibility across multiple drug discount programs, enabling effective compliance monitoring, claim validation, and dispute resolution between manufacturers and covered healthcare providers. The added 340B data also strengthens Model N's advanced analytics strategy, giving manufacturers more complete information across the revenue lifecycle. "Model N delivers the commercial platform life sciences leaders rely on to expand market access, optimize revenue, and maintain compliance," said Bret Connor, CEO of Model N. "Through Kalderos, we are providing a more proactive and precise way to manage complex drug pricing programs through a single, fully integrated revenue management solution. This is critical as pricing programs, rebate requirements, and 340B data demands become more complex." As part of Model N, Kalderos and the Truzo platform gain access to increased scale, customer relationships, and commercial infrastructure to accelerate their impact across the life sciences industry. The unified solution will connect contracting, claims validation, and dispute and payment processes, helping customers act on potential discount issues with clear, supporting data. "Kalderos was built to give manufacturers a transparent, claims-level view of 340B activity, helping them proactively identify non-compliance and reduce revenue leakage," said Angie Franks, Kalderos' CEO. "By joining Model N, we're bringing these capabilities into a revenue management platform already trusted by leading pharmaceutical manufacturers, enabling more informed decisions and better outcomes across the revenue lifecycle." Model N recently announced it now manages $1.3 trillion in gross revenue for pharmaceutical and medical technology customers. The company also recently launched Data nSights, an AI-ready integrated data and analytics solution, and expanded agentic workflows across pricing, deal execution, and gross-to-net. Advisors J.P. Morgan Securities LLC acted as exclusive financial advisor to Kalderos in connection with this transaction. Cooley LLP acted as legal counsel to Kalderos in connection with the transaction. Kirkland & Ellis acted as legal counsel to Model N in connection with the transaction. About Model N For more than 25 years, Model N has been the leader in end-to-end commercialization, revenue optimization, and compliance for pharmaceutical, medtech, and high-tech innovators. With a focus on innovation and customer success, Model N helps manufacturers streamline their revenue operations and remain compliant, empowering them to deliver life-changing products to the world. Its intelligent platform, purpose-built solutions, and advanced analytics and AI automation are trusted by more than 150 of the world's leading companies across more than 120 countries. For more information, visit www.modeln.com. About Kalderos Kalderos is a health technology company focused on delivering an independent, authoritative view of financial operations across the pharmaceutical ecosystem. Through its Truzo platform, Kalderos has created a purpose-built gross-to-net intelligence platform that consolidates claims-level information to enable proactive revenue management decisions. Built on the analysis of billions of dollars in drug purchases and discounts, Kalderos offers clients an unrivaled view of market activity, unifying data across 340B, Medicare, Medicaid, and commercial programs to enable precise, scalable, and auditable insights at the claim level. Headquartered in Chicago, Kalderos was founded in 2016 and continues to pursue its goal of creating an objective source of financial truth for the gross-to-net ecosystem that eliminates misalignments and waste and promotes a more sustainable market for pricing and paying for prescription drugs. To learn more about Kalderos, please visit www.kalderos.com.

Model N appoints Thomas Gibbs to board of directors. May 5, 2026 Seasoned pharmaceutical executive brings over 25 years of commercial leadership to Model N board REDWOOD CITY, Calif., May 5, 2026 - Model N, a leading end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies, announced the appointment of Thomas Gibbs to the company's board of directors. Gibbs has over 25 years of leadership experience across Executive Management, Marketing, Sales, Commercial Operations, and Finance at small, mid-size, and large pharmaceutical companies. He is the Executive Vice President and President of Lundbeck US, a biopharmaceutical company focused exclusively on brain health. Throughout his career, Gibbs has held senior commercial and general management roles at Johnson & Johnson, Novartis, Bristol Myers Squibb, Takeda, Endo Pharmaceuticals, Vanda Pharmaceuticals, OptiNose, and Sunovion. These include Chief Commercial Officer positions overseeing U.S., Canadian, and European markets for companies with leading central nervous system (CNS) franchises. "Tom brings deep pharmaceutical leadership and extensive experience scaling complex, global organizations while driving measurable business impact," said Bret Connor, CEO of Model N. "His strength lies in integrating strategy, analytics, and cross-functional collaboration to help drive sustainable growth. As Model N continues to advance its offerings and expand globally, we believe his expertise will play an important role in our continued momentum." "Life sciences companies face increasing pressure to modernize operations and enable sustainable, data-driven growth, and Model N is uniquely positioned to support that journey," said Gibbs. "I look forward to bringing my experience to help advance Model N's strategy and deliver greater value for its customers." Gibbs' role was sourced through the external board program operated by Vista Equity Partners, a global technology investor that specializes in enterprise software and is a majority investor in Model N. Launched in 2017, the board program leverages Vista's ecosystem and additional resources to identify, train, and appoint qualified board candidates for its portfolio companies. The program works to create a pipeline of highly talented board candidates through programs and partnerships that will drive results for the corporate world at large. About Model N For more than 25 years, Model N has been the leader in end-to-end commercialization, revenue optimization, and compliance for pharmaceutical, medtech, and high-tech innovators. With a focus on innovation and customer success, Model N helps manufacturers streamline their revenue operations and remain compliant, empowering them to deliver life-changing products to the world. Its intelligent platform, purpose-built solutions, and advanced analytics and AI automation are trusted by more than 150 of the world's leading companies across more than 120 countries. For more information, visit www.modeln.com.

Model N expands into global market access through strategic partnership with CCX. Joint offering helps life sciences companies align launch strategy and commercial decisions across global markets REDWOOD CITY, Calif. - March 2, 2026 - Model N, the leading end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies, announced a strategic partnership with CCX, a market leading technology company focused on accelerating global market access and pricing strategy. The partnership extends Model N's platform functionality into earlier phases of the drug lifecycle and expands the company's capabilities beyond pricing and market access operations into global launch pricing strategy. As a result, joint customers can more effectively coordinate pricing strategies and ensure timely launch execution in an increasingly complex regulatory and market access environment. The collaboration enables pharmaceutical manufacturers to quickly model, simulate, and coordinate launch strategies and commercial terms before products reach the market - a critical need as early access decisions can have downstream pricing and revenue implications across global markets. Model N's 2026 State of Revenue Report found that 99% of life sciences leaders say gross-to-net has become more complex. Yet many organizations still manage critical pricing and revenue processes through spreadsheets and manual workflows. This limits their ability to quickly evaluate trade-offs, anticipate cross-market impacts, and identify pricing risks from policies such as most-favored-nation (MFN) before decisions are made. "As gross-to-net complexity continues to rise, life sciences organizations need earlier alignment across market access, global pricing, and revenue planning," said Bret Connor, CEO of Model N. "Market access decisions shape the long-term revenue trajectory of a therapy, and by partnering with CCX, we're extending Model N's platform into global launch planning and strategy. This gives our customers greater visibility from initial market access discussions through execution and revenue management." By combining CCX's market access planning capabilities with Model N's pricing, tender, and revenue management solutions, manufacturers can align strategy across the product lifecycle and support end-to-end commercialization through launch, contracting, and loss of exclusivity. Under the partnership, CCX technology connects directly to Model N's global pricing and tender solutions. This allows manufacturers to model cross-market launch sequencing, evaluate MFN exposure, reference pricing impacts, and assess trade-offs before implementation using data-driven scenario modeling. The integration connects market access planning with contracting, tender management, and rebate processing within a coordinated framework. CCX's platform supports in the moment scenario modeling for launch and loss-of-exclusivity planning, collaboration between headquarters and affiliates, and structured payer negotiations. The company currently supports 76 pharmaceutical assets across 56 countries. "By working with Model N, we can connect market access planning directly to revenue execution," said Nathan Sigworth, CEO of CCX. "Together, we are helping manufacturers launch products more strategically, manage commercial decisions with greater confidence, and foster stronger collaboration with payers to ensure therapies reach the patients who need them." Editor details. * Company: * PharmiWeb * Name: * Editor Last Updated: 04-Mar-2026